Evommune (EVMN) Competitors

$22.74 -0.81 (-3.46%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$22.90 +0.16 (+0.70%)

As of 05/22/2026 04:10 PM Eastern

EVMN vs. BEAM, ERAS, ORKA, ALMS, and RCUS

Should you buy Evommune stock or one of its competitors? MarketBeat compares Evommune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evommune include Beam Therapeutics (BEAM), Erasca (ERAS), Oruka Therapeutics (ORKA), Alumis (ALMS), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.

How does Evommune compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Evommune (NYSE:EVMN) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

In the previous week, Beam Therapeutics had 7 more articles in the media than Evommune. MarketBeat recorded 7 mentions for Beam Therapeutics and 0 mentions for Evommune. Beam Therapeutics' average media sentiment score of 0.00 equaled Evommune'saverage media sentiment score.

Company	Overall Sentiment
Beam Therapeutics	Neutral
Evommune	Neutral

Evommune has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.09	-$79.99M	-$0.68	N/A
Evommune	$10M	81.89	-$68.87M	-$9.50	N/A

Evommune has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Evommune's return on equity of 0.00% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Evommune	N/A	N/A	N/A

Beam Therapeutics presently has a consensus price target of $46.83, indicating a potential upside of 63.52%. Evommune has a consensus price target of $49.25, indicating a potential upside of 116.62%. Given Evommune's stronger consensus rating and higher probable upside, analysts clearly believe Evommune is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00

99.7% of Beam Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Evommune beats Beam Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Evommune compare to Erasca?

Evommune (NYSE:EVMN) and Erasca (NASDAQ:ERAS) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Evommune's return on equity of 0.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Erasca	N/A	-35.31%	-29.49%

67.8% of Erasca shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Evommune has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$10M	81.89	-$68.87M	-$9.50	N/A
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

Evommune presently has a consensus target price of $49.25, indicating a potential upside of 116.62%. Erasca has a consensus target price of $18.75, indicating a potential upside of 66.81%. Given Evommune's stronger consensus rating and higher probable upside, analysts clearly believe Evommune is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Erasca had 10 more articles in the media than Evommune. MarketBeat recorded 10 mentions for Erasca and 0 mentions for Evommune. Evommune's average media sentiment score of 0.00 beat Erasca's score of -0.19 indicating that Evommune is being referred to more favorably in the media.

Company	Overall Sentiment
Evommune	Neutral
Erasca	Neutral

Summary

Evommune beats Erasca on 10 of the 14 factors compared between the two stocks.

How does Evommune compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Evommune (NYSE:EVMN) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

Oruka Therapeutics currently has a consensus target price of $120.80, suggesting a potential upside of 99.31%. Evommune has a consensus target price of $49.25, suggesting a potential upside of 116.62%. Given Evommune's stronger consensus rating and higher probable upside, analysts plainly believe Evommune is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00

56.4% of Oruka Therapeutics shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Oruka Therapeutics had 18 more articles in the media than Evommune. MarketBeat recorded 18 mentions for Oruka Therapeutics and 0 mentions for Evommune. Oruka Therapeutics' average media sentiment score of 0.71 beat Evommune's score of 0.00 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Oruka Therapeutics	Positive
Evommune	Neutral

Evommune has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Evommune	$10M	81.89	-$68.87M	-$9.50	N/A

Evommune's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Evommune	N/A	N/A	N/A

Summary

Evommune beats Oruka Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Evommune compare to Alumis?

Evommune (NYSE:EVMN) and Alumis (NASDAQ:ALMS) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

In the previous week, Alumis had 13 more articles in the media than Evommune. MarketBeat recorded 13 mentions for Alumis and 0 mentions for Evommune. Alumis' average media sentiment score of 0.60 beat Evommune's score of 0.00 indicating that Alumis is being referred to more favorably in the news media.

Company	Overall Sentiment
Evommune	Neutral
Alumis	Positive

Evommune presently has a consensus target price of $49.25, indicating a potential upside of 116.62%. Alumis has a consensus target price of $40.30, indicating a potential upside of 83.02%. Given Evommune's stronger consensus rating and higher probable upside, equities research analysts plainly believe Evommune is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Evommune has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Evommune's return on equity of 0.00% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Alumis	-2,825.70%	-88.79%	-70.72%

Evommune has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$10M	81.89	-$68.87M	-$9.50	N/A
Alumis	$24.05M	116.73	-$243.32M	-$1.98	N/A

Summary

Evommune beats Alumis on 8 of the 13 factors compared between the two stocks.

How does Evommune compare to Arcus Biosciences?

Evommune (NYSE:EVMN) and Arcus Biosciences (NYSE:RCUS) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Evommune has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Evommune's return on equity of 0.00% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Evommune currently has a consensus price target of $49.25, suggesting a potential upside of 116.62%. Arcus Biosciences has a consensus price target of $33.89, suggesting a potential upside of 44.36%. Given Evommune's stronger consensus rating and higher possible upside, equities analysts clearly believe Evommune is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

In the previous week, Arcus Biosciences had 1 more articles in the media than Evommune. MarketBeat recorded 1 mentions for Arcus Biosciences and 0 mentions for Evommune. Evommune's average media sentiment score of 0.00 equaled Arcus Biosciences'average media sentiment score.

Company	Overall Sentiment
Evommune	Neutral
Arcus Biosciences	Neutral

Evommune has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$10M	81.89	-$68.87M	-$9.50	N/A
Arcus Biosciences	$247M	11.95	-$353M	-$3.18	N/A

92.9% of Arcus Biosciences shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Evommune beats Arcus Biosciences on 10 of the 15 factors compared between the two stocks.

Get Evommune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVMN vs. The Competition

Export

Metric	Evommune	Industry	Manufacturing Sector	NYSE Exchange
Market Cap	$848.22M	$2.98B	$4.24B	$23.06B
Dividend Yield	N/A	15.25%	6.20%	4.09%
P/E Ratio	-2.39	13.06	21.96	30.66
Price / Sales	81.89	1,848.57	178.79	23.71
Price / Cash	N/A	26.32	54.04	25.15
Price / Book	2.69	6.12	34.84	4.73
Net Income	-$68.87M	-$42.06M	$112.32M	$1.07B
7 Day Performance	-0.10%	0.88%	1.84%	1.94%
1 Month Performance	-11.73%	1.87%	3.83%	0.85%
1 Year Performance	N/A	18.72%	16.01%	28.44%

Evommune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVMN Evommune	2.8357 of 5 stars	$22.74 -3.5%	$49.25 +116.6%	N/A	$848.22M	$10M	N/A	45
BEAM Beam Therapeutics	3.2936 of 5 stars	$29.53 -7.3%	$46.83 +58.6%	+66.1%	$3.28B	$139.74M	N/A	510	Analyst Forecast
ERAS Erasca	3.5465 of 5 stars	$10.37 -0.9%	$18.75 +80.8%	+828.9%	$3.25B	N/A	N/A	120
ORKA Oruka Therapeutics	3.6652 of 5 stars	$63.90 +1.1%	$120.80 +89.0%	+441.6%	$3.17B	N/A	N/A	N/A	Insider Trade Analyst Revision
ALMS Alumis	3.5267 of 5 stars	$24.63 -0.9%	$38.60 +56.7%	+355.0%	$3.16B	$24.05M	N/A	N/A	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EVMN) was last updated on 5/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evommune (EVMN) Competitors

EVMN vs. BEAM, ERAS, ORKA, ALMS, and RCUS

How does Evommune compare to Beam Therapeutics?

Summary

How does Evommune compare to Erasca?

Summary

How does Evommune compare to Oruka Therapeutics?

Summary

How does Evommune compare to Alumis?

Summary

How does Evommune compare to Arcus Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evommune (EVMN) Competitors

EVMN vs. BEAM, ERAS, ORKA, ALMS, and RCUS

How does Evommune compare to Beam Therapeutics?

Does the media prefer BEAM or EVMN?

Which has higher valuation and earnings, BEAM or EVMN?

Is BEAM or EVMN more profitable?

Do analysts prefer BEAM or EVMN?

Do insiders and institutionals believe in BEAM or EVMN?

Summary

How does Evommune compare to Erasca?

Is EVMN or ERAS more profitable?

Do institutionals & insiders have more ownership in EVMN or ERAS?

Which has stronger valuation and earnings, EVMN or ERAS?

Do analysts recommend EVMN or ERAS?

Does the media prefer EVMN or ERAS?

Summary

How does Evommune compare to Oruka Therapeutics?

Do analysts prefer ORKA or EVMN?

Do insiders & institutionals hold more shares of ORKA or EVMN?

Does the media favor ORKA or EVMN?

Which has stronger valuation and earnings, ORKA or EVMN?

Is ORKA or EVMN more profitable?

Summary

How does Evommune compare to Alumis?

Does the media prefer EVMN or ALMS?

Do analysts recommend EVMN or ALMS?

Is EVMN or ALMS more profitable?

Which has higher valuation & earnings, EVMN or ALMS?

Summary

How does Evommune compare to Arcus Biosciences?

Is EVMN or RCUS more profitable?

Do analysts rate EVMN or RCUS?

Does the media prefer EVMN or RCUS?

Which has higher valuation & earnings, EVMN or RCUS?

Do institutionals & insiders hold more shares of EVMN or RCUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools